Success Stories: An Indian Staff Scientist in Biotechnology Gets NIW Approval without RFE, Thanks to Our Team’s Work with the Case Preparation
Client’s Testimonial:
“Thank you, guys! The whole process was very streamlined and easy, and I was surprised it got approved this fast. Thank you again.”
On January 28th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Staff Scientist in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Staff Scientist
Country of Origin: India
State of Residence at the Time of Filing: New York
Approval Notice Date: January 28th, 2023
Processing Time: 3 months, 16 days
Case Summary:
As an expert in the field of biotechnology, our NIW (National Interest Waiver) client’s proposed endeavor was to work on elucidating the genetic mechanisms underlying neurodegenerative diseases using his expertise in neurodegenerative disease and biochemistry, genetics, and molecular biology techniques. He wanted to identify new bio targets for the treatment of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions through his research.
So, while preparing his case for submission to the USCIS, we collected the following data for his petition:
- His research advancing his proposed endeavor is of great importance because it provides unprecedented insight into models of the neuronal mechanisms underlying neuronal degeneration, the central phenomenon involved in diseases and disorders like dementia, which includes Alzheimer’s disease, the most common form of dementia. By elucidating these neuronal processes, he has illuminated the neuronal basis of this debilitating and often lethal class of syndromes.
- His proposed endeavor also has broad implications for the United States, wherein the identification of new neurological targets for the treatment of major neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease is of major economic as well as medical importance.
- He has repeatedly equipped researchers and drug makers with state-of-the-art insights and models of the genetic and molecular complexes underlying major neurological diseases and disorders and aging, which is imperative for identifying new neuron-level bio targets for the treatment of debilitating neurological conditions, including but not limited to Alzheimer’s disease, Parkinson’s disease, and other dementias.
- Due to his knowledge and expertise in neurodegenerative disease and biochemistry, genetics, and molecular biology techniques, he has been regularly invited to conduct peer reviews for authoritative journals in the field.
- His research has resulted in 6 peer-reviewed journal articles (3 of them first-authored and 1 of them co-first-authored) which have been cited a total of 27 times.
- Finally, his work has been appreciated by recommenders who furnished him with letters appraising his work.